Related Experiment Video
Updated: Mar 19, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Utilizing G2/M retention effect to enhance tumor accumulation of active targeting nanoparticles
Guanlian Hu1, Xingli Cun1, Shaobo Ruan1
1Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, China.
Abstract:
In recent years, active targeting strategies by ligand modification have emerged to enhance tumor accumulation of NP, but their clinical application was strictly restricted due to the complex preparation procedures, poor stability and serious toxicity. An effective and clinical translational strategy is required to satisfy the current problems. Interestingly, the internalization of NP is intimately related with cell cycle and the expression of receptors is not only related with cancer types but also cell cycle progression. So the cellular uptake of ligand modified NP may be related with cell cycle. However, few investigations were reported about the relationship between cell cycle and the internalization of ligand modified NP. Herein, cellular uptake of folic acid (FA) modified NP after utilizing chemotherapeutic to retain the tumor cells in G2/M phase was studied and a novel strategy was designed to enhance the active targeting effect. In our study, docetaxel (DTX) notably synchronized cells in G2/M phase and pretreatment with DTX highly improved in vitro and in vivo tumor cell targeting effect of FA decorated NP (FANP). Since FA was a most common used tumor active targeting ligand, we believe that this strategy possesses broader prospects in clinical application for its simplicity and effectiveness.
Insights
This study shows that synchronizing tumor cells in the G2/M phase with docetaxel (DTX) enhances the tumor targeting of folic acid (FA) modified nanoparticles (NPs). This simple strategy improves nanoparticle delivery for potential cancer therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Active targeting of nanoparticles (NPs) to tumors via ligand modification faces challenges in clinical translation due to complex preparation, poor stability, and toxicity.
- Nanoparticle internalization is linked to the cell cycle, and receptor expression varies with cancer type and cell cycle stage.
Purpose of the Study:
- To investigate the relationship between cell cycle and ligand-modified NP internalization.
- To develop a novel strategy for enhancing active tumor targeting of NPs by manipulating the cell cycle.
Main Methods:
- Utilized chemotherapeutics to synchronize tumor cells in the G2/M phase.
- Studied the cellular uptake of folic acid (FA) modified NPs (FANPs) in G2/M synchronized cells.
- Evaluated the in vitro and in vivo targeting efficacy of DTX-pretreated FANPs.
Main Results:
- Docetaxel (DTX) effectively synchronized tumor cells in the G2/M phase.
- Pretreatment with DTX significantly improved the in vitro and in vivo tumor cell targeting of FA-decorated NPs (FANPs).
Conclusions:
- Cell cycle synchronization is a viable strategy to enhance the active targeting of ligand-modified NPs.
- This DTX-induced G2/M phase arrest strategy offers a simple and effective method for improving FANP tumor accumulation, with broad clinical application prospects.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Targeted Cancer Therapies
There are several types of targeted therapies against...
Site-Targeted Drug Delivery Systems: Polymeric Carriers

